Catalyst Pharmaceuticals, Inc. (CPRX) P/E Ratio History
Fairly ValuedTrading at 18.7x, near 5Y avg of 18.1x · 60th percentile · In line with own history · Data 2019–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Catalyst Pharmaceuticals, Inc. (CPRX) trades at a price-to-earnings ratio of 18.7x, with a stock price of $31.38 and trailing twelve-month earnings per share of $1.74.
The current P/E is roughly in line with its 5-year average of 18.1x. Over the past five years, CPRX's P/E has ranged from a low of 8.2x to a high of 29.5x, placing the current valuation at the 60th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CPRX trades at a 16% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 0.99 (P/E divided by 28% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, CPRX trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CPRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CPRX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CPRX P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.4Lowest | -Best | +68% | |
| $7B | 10.2 | -Best | +264%Best | |
| $7B | 31.5 | -Best | -34% | |
| $2B | 12.3 | -Best | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CPRX Historical P/E Data (2019–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $24.76 | $1.73 | 14.3x | -19% |
| FY2025 Q4 | Dec 31 2025 | $23.34 | $1.68 | 13.9x | -21% |
| FY2025 Q3 | - | $19.70 | $1.72 | 11.5x | -35% |
| FY2025 Q2 | Jun 30 2025 | $21.70 | $1.65 | 13.2x | -25% |
| FY2025 Q1 | Mar 31 2025 | $24.25 | $1.57 | 15.4x | -12% |
| FY2024 Q4 | - | $20.87 | $1.31 | 15.9x | -9% |
| FY2024 Q3 | Sep 30 2024 | $19.88 | $1.18 | 16.8x | -4% |
| FY2024 Q2 | Jun 30 2024 | $15.49 | $0.54 | 28.7x | +63% |
| FY2024 Q1 | Mar 31 2024 | $15.94 | $0.54 | 29.5x | +68% |
| FY2023 Q4 | Dec 31 2023 | $16.81 | $0.61 | 27.6x | +57% |
| FY2023 Q3 | Sep 30 2023 | $11.69 | $0.52 | 22.5x | +28% |
| FY2023 Q2 | Jun 30 2023 | $13.44 | $1.01 | 13.3x | -24% |
| FY2023 Q1 | Mar 31 2023 | $16.58 | $0.88 | 18.8x | +7% |
| FY2022 Q4 | Dec 31 2022 | $18.60 | $0.74 | 25.1x | +43% |
| FY2022 Q3 | Sep 30 2022 | $12.83 | $0.61 | 21.0x | +20% |
| FY2022 Q2 | - | $7.01 | $0.51 | 13.7x | -22% |
| FY2022 Q1 | - | $8.29 | $0.42 | 19.7x | +12% |
| FY2021 Q4 | Dec 31 2021 | $6.77 | $0.37 | 18.3x | +4% |
| FY2021 Q3 | - | $5.30 | $0.39 | 13.6x | -23% |
| FY2021 Q2 | Jun 30 2021 | $5.75 | $0.70 | 8.2x | -53% |
| FY2021 Q1 | Mar 31 2021 | $4.61 | $0.68 | 6.8x | -61% |
| FY2020 Q4 | - | $3.34 | $0.71 | 4.7x | -73% |
| FY2020 Q3 | Sep 30 2020 | $2.97 | $0.67 | 4.4x | -75% |
| FY2020 Q2 | - | $4.62 | $0.39 | 11.8x | -33% |
| FY2020 Q1 | - | $3.85 | $0.40 | 9.6x | -45% |
| FY2019 Q4 | - | $3.75 | $0.29 | 12.8x | -27% |
| FY2019 Q3 | Sep 30 2019 | $5.31 | $0.08 | 63.4x | +261% |
Average P/E for displayed period: 17.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CPRX — Frequently Asked Questions
Quick answers to the most common questions about buying CPRX stock.
What is CPRX's P/E ratio?
Catalyst Pharmaceuticals, Inc. (CPRX) trailing twelve-month P/E ratio is 18.7x, based on TTM diluted EPS of $1.74. The 5-year average P/E is 18.1x and the historical range spans 8.2x to 29.5x.
Is CPRX stock overvalued or undervalued?
CPRX trades at 18.7x P/E, near its 5-year average of 18.1x. The 60th percentile ranking within the 8.2x–29.5x historical range places valuation within normal bounds.
Is CPRX stock expensive?
CPRX is fairly valued relative to its own history. The current P/E of 18.7x is near the 5-year average of 18.1x (60th percentile of historical range).
What is CPRX's historical P/E range?
Over the past 5 years, CPRX's P/E ratio has ranged from 8.2x to 29.5x, with a median of 16.8x and an average of 18.1x. The current P/E of 18.7x places the stock at the 60th percentile of this range. Full historical data spans 2019–2026.
How does CPRX's P/E compare to the S&P 500?
CPRX trades at 18.7x P/E versus the S&P 500 median of 24.4x. The 23% discount to the market suggests lower growth expectations or perceived higher risk.
How does CPRX's valuation compare to Healthcare peers?
Catalyst Pharmaceuticals, Inc. P/E of 18.7x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CPRX's PEG ratio?
CPRX PEG ratio is 0.99, based on a P/E of 18.7x and EPS growth of 28.2%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.
What is CPRX's earnings yield?
CPRX earnings yield is 5.35%, the inverse of its 18.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.